Selective ciclo-oxygenasa 2 (COX-2)-inhibitor antiinflamatory drugs;Antinflamatorios inhibidores selectivos de la cicloxigenasa-2 (COX-2)

Alergologia e Inmunologia Clinica

Volumn 17, Issue 5, 2002, Pages 247-254

  Gonzalez Perez R ^a   Poza Guedes, P ^a   Vives, R ^a   Canto, G ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; MELOXICAM; NIMESULIDE; ROFECOXIB;

HUMAN; REVIEW; SIDE EFFECT;

EID: 0036818283     PISSN: 1575734X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Jepson P. NSAID Prescribing in Europe[DM Thesis] Newcastle upon Tyne, UK University of Newcastle upon Tyne; 2000.
2. Jones R. Nonsteroidal anti-inflammatory drug prescribing: Past, present and future. Am J Med 2001; 110: 4S-7S.
3. Hirschberg H. Mittheilung über einen von debewirkung des aspirin. Deutsche Med Wochenschi 1902; i: 416-417.
4. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheum (Suppl.) 1991; 28: 6-10.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology 1971; 231: 232-235.
6. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971; 231: 235-237.
7. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature 1971; 231: 237-239.
8. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and supression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-16740.
9. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314.
10. Gierse J, McDonald J, Hauser S, Rangwala SH, Koboldt CM, Seibert K. A single aminoacid difference between cyclooxygenase-1 (COX-1) and -2(COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271: 15810-15814.
11. Cryer B, Feldman M. Cyclooxygenase-1 and Cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-421.
12. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-143.
13. Gans KR, Galbraith W, Roman RJ, Harber SB, Kerr JS, Schmidt WK. Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180-187.
14. Futaki N, Takahashi S, Yokoyama M, Arai I, Miguchi S, Otomu S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-59.
15. Noble S, Balfour JA. Meloxicam. Drugs 1996; 51: 424-432.
16. Geiss GS, Hubbard RC, Callison DA, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor. Rheumatol Eur 1998; 27: 118.
17. Salido M, Abásolo L, Bañares A. Revisión de los antiinflamatorios inhibidores selectivos de la ciclooxigenasa-2. Información Terapéutica del Sistema Nacional de Salud 2001; 25: 46-52.
18. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs do they really offer any advantages? Drugs 2000; 59: 1207-1216.
19. Knowles S, Shaphiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drugs Saf 2001; 24: 239-247.
20. Feliú A, Lozoya C, Jiménez A, Canto G. Reacción adversa a inhibidores de la COX-2: A propósito de 3 casos. Alergol Inmunol Clin (en prensa).
21. Enrique E, Cisteró-Bahíma A, San Miguel-Moncín MM, Alonso R. Rofecoxib should be tried in NSAID hypersensitivity. Allergy 2000; 55: 1090.
22. Asero R. Tolerability of rofecoxib. Allergy 2001; 56: 916-917.
23. Sáchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Pérez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions Ann Allergy Asthma Immunol 2001; 87: 201-204.
24. Bianco S, Robuschi M, Petrigni G, Scury M, Pieroni MG, Refini RM. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993; 46 (Suppl.1): 115-120.
25. Mori JE, Guerra FT. Nimesulide as an alternative in patients with allergic reactions, to NSAIDs. J Allergy Clin Immunol 1997; 104: s343.
26. Barranco P, Muñoz Robles ML, Caballero MT, Cabañas R, Rodriguez Alarcón C, López Serrano MC. Tolerance to nimesulide in no steroidal antiinflamatory drugs intolerant patients. J Allergy Clin Immunol 1998; 105 (Suppl 1): s273.
27. Bavbek S, Celik G, Ediger D, Mungan D, Demirel YS, Mysidigilz Z. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal antiinflamatory drug intolerance. J Asthma 1999; 36: 657-663.
28. Yoshida S, Ishizaki Y, Onuma K, Nakagawa H, Amayasu H. Selective cyclo-oxigenase 2 inhibitor in patients with aspirin induced asthma J Allergy Clin Immunol 2000; 13: 1201-1202.
29. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance N Engl J Med 2001; 344: 142.
30. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31: 219-225.
31. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108: 47-55.
32. Zollner TM, Ahlbach S, Kaufmann R, Boehncke WH. Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal antiinflamatory agents. Dtsch Med Wochenschr 2001; 126: 386-388.
33. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or nonsteroidal antiinflamatory drugs. Clin Exp Allergy 2002; 32: 397-400.
34. Martín-García C, Hinojosa M, Berges P, Camacho E, García Rodríguez R, Alfara T, et al. Safety of a cyclooxygenase-2 inhibitor. Chest 2002; 121: 1812-1817.
35. Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89: 63-66.
36. Cueva Oliver B, Vives Conesa R, Canto Díez G, Barbarroja Escudero J, Herráez Herrera P, Rivas-Plata Sierra C. Nimesulida: fármaco alternativo en pacientes con intolerancia a AINEs. Alergol Inmunol Clin 1998; 13: 193.
37. Luna Ortiz I, Marcos Bravo C, González Vázquez R. Tolerancia a nimesulida en pacientes con idiosincrasia. Rev Esp Alergol Inmunol Clin 1998; 13: 194.
38. Ortega N, Álvarez JM, Almeida L. Nimesulida: ¿Una nueva alternativa en pacientes con intolerancia a antiinflamatorios no esteroideos? Alergol Inmunol Clin 1998; 13: 195.
39. Valero Santiago A, González Morales MA, Montoro Lacomba J, Malet Casajuana A. Nimesulida como tratamiento alternativo en pacientes con intolerancia a los antiinflamatorios no esteroideos. Alergol Inmunol Clin 1998; 13: 336-338.
40. González Mahave I, Anda M, Bernedo M, Audícana MT, Gastaminza G, Fernández E. Inhibidores de la COX-2: Tolerabilidad en pacientes con intolerancia a AINEs. Alergol Inmunol Clin 2000; 15: 25-26.
41. Garrido Serrano P, Poza Guedes P, Vives R, Rivas-Plata Sierra C, González Pérez R, Rosado Ingelmo A, et al. Rofecoxib ¿fármaco alternativo en pacientes con intolerancia a AINEs (IA)? Alergol Inmunol Clin 2000; 15: 53.
42. Madera J, Diez B. Tolerancia a rofecoxib en intolerants a AINEs. Alergol Inmunol Clin 2000; 15: 57.
43. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21: 2065-2079.
44. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001; 87: 72-73.
45. Grob M, Pichler WJ, Wüthrich B. Anaphylaxis to celecoxib. Allergy 2002; 57: 264-265.
46. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 2001; 28: 2553-2554.
47. Grob M, Scheidegger P, Wuthrich B. Allergic skin reaction to celecoxib. Dermatology 2000; 201: 383.
48. Verbeiren S, Morant C, Charlanne H, Ajebbar K, Cazon J, Modiano P. Celecoxib-induced toxiderma with positive patch test. Ann Dermatol Venereol 2002; 129: 203.
49. Fye KH, Crowley E, Berger TG, LeBoit PE, Connolly MK. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol 2001; 45: 300-302.
50. Schneider F, Meziani F, Chartier C, Alt M, Jaeger A. Fatal allergic vasculitis associated with celecoxib. Lancet 2002; 359: 852-853.
51. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pinkust, Wheltas A. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflamatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomised controlled trial. JAMA 2000; 284: 1247-1255.
52. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, for the VIGOR Study Group. Comparision of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
53. McCormick PA, Kennedy F, Curry M, Traynor O.COX-2 inhibitor and fulminant hepatic failure. Lancet 1999; 353: 40-41.
54. Villa G. NSAIDs and hepatic reactions. Lancet 1999; 353: 846.
55. Boelsterli CA. Mechanisms of NSAIDs-induced hepatotoxicity: Focus on nimesulide. Drug Saf 2002; 25: 633-648.
56. Grignola JC, Arias L, Rondán N, Solá L, Bagnulo H. Hepatotoxicidad asociada a la nimesulida. Arch Med Intern 1998; 20: 13-18.
57. R.A.M. Boletín Informativo del Centro de Farmacovigilancia de la Comunidad de Madrid, mayo 2002;9:1-5.